Rotigotine
Frontotemporal Dementia
I.R.C.C.S. Fondazione Santa LuciaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the Frontotemporal Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Flortaucipir Mayo Clinic | Phase 4 | BBB |
Fludeoxyglucose University of Michigan | Phase 4 | BB |
Citalopram Sunnybrook Health Sciences Centre | Phase 4 | BB |
Lemborexant Nova Scotia Health Authority | Phase 4 | BB |
Pittsburgh Compound B Unlabelled Mayo Clinic | Phase 4 | BB |
View all 38 →
Same molecule, other indications
Rotigotine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →